Related Experiment Videos
Combination-therapy cyclosporin-A--etretinate for psoriasis
M J Korstanje1, W J van de Staak
1Department of Dermatology, Academic Hospital Maastricht, The Netherlands.
Clinical and Experimental Dermatology
|May 1, 1990
Summary
Cyclosporin effectively treated plaque psoriasis in five patients. Adding etretinate provided no additional therapeutic benefit for persistent or relapsed cases.
Area of Science:
- Dermatology
- Immunosuppressive Therapy
Background:
- Psoriasis is a chronic inflammatory skin condition.
- Therapy-resistant psoriasis poses a significant clinical challenge.
Purpose of the Study:
- To evaluate the efficacy of cyclosporin in plaque-type psoriasis.
- To assess the additive effect of etretinate when added to cyclosporin therapy.
Main Methods:
- Five patients with therapy-resistant plaque psoriasis were enrolled.
- Treatment involved cyclosporin, with etretinate added for non-responders or relapsed cases.
Main Results:
- Cyclosporin demonstrated therapeutic effects in the studied patients.
- No additive therapeutic benefit was observed with the addition of etretinate.
Conclusions:
- Cyclosporin is a viable treatment option for therapy-resistant plaque psoriasis.
- Etretinate does not appear to enhance cyclosporin's efficacy in this patient cohort.